July 19, 2024

Novo Nordisk’s stock slumps after study finds Wegovy lags Lilly’s Mounjaro in speed and scale of weight loss

 Novo Nordisk’s stock slumps after study finds Wegovy lags Lilly’s Mounjaro in speed and scale of weight loss

Novo Nordisk’s stock slumps after study finds Wegovy lags Lilly’s Mounjaro in speed and scale of weight loss

The stock of Danish biotech Novo Nordisk was down 2.2% Tuesday, after a study found that the company’s obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.’s Mounjaro, in speed and magnitude of weight loss.